Carbachol/brimonidine, sold under the brand name Yuvezzi, is a fixed-dose combination medication used for the treatment of presbyopia. It contains carbachol, a cholinergic agonist; and brimonidine, as the salt brimonidine tartrate, an alpha-adrenergic receptor agonist. It is given via an eye drop.
Carbachol/brimonidine was approved for medical use in the United States in January 2026.
Medical uses The combination is indicated for the treatment of presbyopia in adults.
Mechanism of action The combination works by combining carbachol and brimonidine tartrate, the tartrate salt form of brimonidine to work together to constrict the pupil, called miosis.
Carbachol Carbachol constricts the pupil, creating a pinhole effect which lets only the most direct and focused light into the eye. This results in closer objects appearing clearer.
Brimonidine Brimonidine keeps the pupil from widening again by relaxing opposing muscles in the iris and reducing unnecessary muscle activity. This results in the pupil-constricting effect carbachol does to last longer and remain more controlled. This maintains pupil size that supports clear near vision throughout the day.
Society and culture Legal status Carbachol/brimonidine was approved for medical use in the United States in January 2026.
Brand names Carbachol/brimonidine is sold under the brand name Yuvezzi.
References
External links